SCHEMBL186302

SCHEMBL186302

N=C(N)NCCCC1NCC(C(=O)O)NC1=O

nearest known ligand 0.38

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 3/20 0.38
SIRT2 Q8IXJ6 6/20 0.36
SIRT1 Q96EB6 6/20 0.36
SIRT3 Q9NTG7 6/20 0.36
ITGB3 P05106 7/20 0.35
ITGA2B P08514 7/20 0.35
FURIN P09958 1/20 0.32
SIRT5 Q9NXA8 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14385293 1.00 TPSAB1 (0.38) TPSAB1SIRT2SIRT1SIRT3ITGB3
SCHEMBL14385292 1.00 TPSAB1 (0.38) TPSAB1SIRT2SIRT1SIRT3ITGB3
SCHEMBL2735620 1.00 TPSAB1 (0.38) TPSAB1SIRT2SIRT1SIRT3ITGB3
SCHEMBL10186970 1.00 TPSAB1 (0.38) TPSAB1SIRT2SIRT1SIRT3ITGB3
SCHEMBL2735621 1.00 TPSAB1 (0.38) TPSAB1SIRT2SIRT1SIRT3ITGB3
SCHEMBL14394101 0.91 SIRT2 (0.43) TPSAB1SIRT2SIRT1SIRT3SIRT5
SCHEMBL12235966 0.89 SIRT2 (0.40) TPSAB1SIRT2SIRT1SIRT3ITGB3
SCHEMBL10186972 0.89 SIRT2 (0.40) TPSAB1SIRT2SIRT1SIRT3ITGB3
SCHEMBL12235967 0.89 SIRT2 (0.40) TPSAB1SIRT2SIRT1SIRT3ITGB3
SCHEMBL2735622 0.86 TPSAB1 (0.30) TPSAB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114844-B2 Linear and cyclic melanocortin receptor-specific peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2012-02-14 US disclosed
US-8114844-B2 Linear and cyclic melanocortin receptor-specific peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2012-02-14 US disclosed
EP-2004352-B1 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2012-01-04 EP disclosed
EP-2004352-B1 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2012-01-04 EP disclosed
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates PALATIN TECHNOLOGIES, INC. (US) 2011-10-27 US disclosed
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates PALATIN TECHNOLOGIES, INC. (US) 2011-10-27 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-20090069224-A1 Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2009-03-12 US disclosed
US-20090069224-A1 Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2009-03-12 US disclosed
EP-2004352-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-24 EP disclosed
WO-2007115164-A9 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2007-11-29 WO disclosed
WO-2007115164-A9 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2007-11-29 WO disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed
WO-2007115164-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
WO-2007115164-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates ARGLU1, QRFPR, ARG1 TPSAB1 2433/4885SIRT2 3293/4885SIRT1 3416/4885
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs ARGLU1, ARG1, QRFPR TPSAB1 1873/4885SIRT2 1440/4885SIRT1 1798/4885
US-20090069224-A1 Linear and Cyclic Melanocortin Receptor-Specific Peptidomimetics MC1R, MC3R, MC5R TPSAB1 1021/4885SIRT2 3606/4885SIRT1 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.